

Meeting details

Subject	JPAC Board
Date	Thursday 19 June 2025
Time	10:00 to 13:00
Location	Microsoft Teams

JPAC Office

Clare Denison	CD	Deputy Director, JPAC	
Gary Mallinson	GMA	Scientific Lead for Safety Policy, JPAC/SaBTO	
Peter Rae	PR	Scientific Publishing Manager, JPAC	(Minutes)
Stephen Thomas	ST	Professional Director, JPAC	(Chair)
Anna Witham	AW	Administrator, JPAC	

Executive Working Group

Emyr Adlam	EA	Chair, Standing Advisory Committee on Information Technology (SACIT)	
Kenny Douglas	KD	Chair, SAC on Cellular Therapy Products (SACCTP)	
Ryan Evans	RE	Chair, SAC on Blood Components (SACBC)	
Dora Foukaneli	DF	Clinical Transfusion Medicine Specialist, JPAC	
Jayne Hughes	JH	Deputy Chair, SAC on Care and Selection of Donors (SACCSD)	
Richard Lomas	RL	Chair, SAC on Tissues (SACT)	
Kate Tettmar	KT	Deputy Chair – Scientific, SAC on Transfusion Transmitted Infection (SACTTI)	

JPAC Board

Allameddine Allameddine	AA	Medical Director, NIBTS	
Neil Almond	NA	MHRA South Mimms Laboratories	
Richard Ballerand	RB	Lay representative, JPAC	
Andrew Godfrey	AG	Medical Director, IBTS	(Observer)
Evelyn McLennan	EMc	Chair, UK Quality Managers Group	
Lorna McLintock	LM	Medical Director, SNBTS	
Gail Miflin	GMI	Chief Medical Officer, NHSBT	
David Olszowka	DO	Regulatory Governance Lead, MHRA	
Helen Percival	HP	Lay representative, JPAC	
Amy Shackell	AS	Regulation Manager, HTA	
Indu Thakur	IT	Deputising for Medical Director, WBS	

Guests

Rebecca Cardigan	RC	Member, SACBC	(attending for item 3.1)
Lise Estcourt	LE	Medical Director – Transfusion, NHSBT	(Observer)
Renata Gomes	RG	Chief Scientific Officer, NHSBT	(Observer)
Laura Green	LG	Member, SACBC	(attending for item 3.1)
Katie Hands	KH	Associate Medical Director, SNBTS	(Observer)

Apologies

Edwin Massey	EMa	Medical Director, WBS	
Shruthi Narayan	SN	Medical Director, SHOT	(Observer)
Nicole Thornton	NT	Chair, Standing Advisory Committee on Immunohaematology (SACIH)	
Ines Ushiro-Lumb	IUL	Chair, SACTTI	

Agenda items	Action
1. Welcome and apologies New members were welcomed to their first JPAC Board meeting: • EA attended as the new Chair of SACIT • JH attended as the interim Chair of SACCSD • RB and HP attended as lay representatives Other members, deputies, guests and apologies as noted.	
2. Minutes and actions 2.1. Minutes of the JPAC Board meeting on 20 March 2025 (JPAC 25-30) Approved for publication on the website, pending suggested amendment (under 6.1, ‘use of particular components’ should read ‘provision of particular components’). 2.2. Action list (JPAC 25-31) • Bleeding Disorders – removal of deferral of contacts (JPAC 14.03.24, item 5.1a) • CNs Disease – medication guidance to be clarified (JPAC 14.03.24, item 5.1b) Both added to SACCSD workplan for submission to a future JPAC Board meeting. Actions closed. • Position Statement on JPAC/SaBTO relationship – SaBTO approval to publish (JPAC 20.03.25, item 5.3a) The SaBTO secretariat has indicated verbal approval. Written approval awaited. • Discuss clinical indications for Red Cells and Plasma, LD with BSH writing group (JPAC 20.03.25, item 5.1a) The writing group has prepared an addendum to the current BSH Guideline ‘Haematological management of major haemorrhage’ to include the proposed clinical indications of LD-RCP, which has been submitted to the BSH Task Force group for review and finalisation. Action closed. 2.3. Workplan – summary of open items expected in 2025/26 (JPAC 25-32) Members were invited to review the summary and indicate any items requiring reprioritisation. The full workplan was also provided for information (JPAC 25-39).	PR GMa
3. Standing Advisory Committee on Blood Components (SACBC) 3.1. Provisional specification: Dried Plasma, Leucocyte Depleted (JPAC 25-33) The provisional specification was approved for publication in Annexe 3 of the Red Book. It was agreed that additional data is not required to be submitted to a future JPAC Board meeting but that the JPAC Board will be informed, via SACBC, of any relevant areas of concern that arise.	PR

3.2. Provisional specification: Platelets, Apheresis, in Additive Solution and Plasma, LD (JPAC 25-34)

The provisional specification was approved for publication in Annexe 3 of the Red Book.

PR

Once completed, Phase 1 and Phase 2 study data will be reviewed by SACBC and submitted for discussion by the JPAC Board as required.

4. Standing Advisory Committee on Care and Selection of Donors (SACCSd)

4.1. Injectable Pre-Exposure Prophylaxis (PrEP) for HIV – WB-DSG (JPAC 25-35)

A minor amendment was suggested to clarify that deferral periods should be applied from the date a donor last received oral or injectable PrEP.

Approved for publication, pending this amendment.

PR

5. Standing Advisory Committee on Transfusion Transmitted Infection (SACTTI)

5.1. Annual Surveillance Report 2024 (JPAC 25-36)

This report is prepared annually to provide the JPAC Board with oversight of the monthly Emerging Infection Report (EIR) review process. Thanks were given to the EIR review group and the report's authors, recognising the significant amount of work involved and assurance that the process is robust and effective.

The new narrative summary was considered to be particularly helpful, and it was agreed that the tables of EIR examples could be removed from future versions of the report. Reviewed EIRs will be available from the JPAC Office on request, if required.

5.2. Update on Government Internal Audit Agency (GIAA) Emerging Infections Audit

Initial feedback from the auditors has been positive. The final report is expected shortly.

6. Pandemic preparedness

UK Forum has previously requested that JPAC consider how the UK Blood Services (UKBS) should prepare for a future blood borne pandemic. The JPAC Board suggested several amendments to the outline plan previously prepared with input from relevant members of the EWG (JPAC 25-37).

A gap analysis between this plan's recommendations and the mechanisms already in place within each UKBS could be carried out to understand how effectively the suggested responses could be triggered.

Exercise PEGASUS, a high-level preparedness exercise, is being planned by the UK Government Office for Science for Autumn 2025. JPAC may also consider a business continuity exercise to aid in the development and implementation of this plan.

Additional comments were requested to be sent to **ST** by 31 July 2025, ahead of revision and submission to the UK Forum meeting on 05 September 2025.

All

7. European regulatory activities

The Substances of Human Origin (SoHO) Regulation will come into force in 2027 and the existing EU Directives, upon which the UK's Blood Safety and Quality Regulations (BSQR) and Tissue Safety and Quality Regulations (TSQR) are based, will be rescinded. While it will not apply to Great Britain, Northern Ireland will be subject to the SoHO Regulation in order to align with the Republic of Ireland through the Windsor Framework.

DHSC has commissioned SaBTO to assess the requirements for any future UK legislation by comparing current UK legislation with the SoHO Regulation and the EDQM Blood Guide and Tissues and Cells Guides (as technical annexes). The first phase of this assessment has been completed with responses received from relevant UK regulators. Further discussion is now required to agree an approach for JPAC's input into the review.

8. Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)

A summary report of the activities of SaBTO and its working groups was provided ([JPAC 25-38](#)).

The next SaBTO meeting will be held on 11 September 2025.

9. Any other business

9.1. Interpreters – changes to the Red Book and WB-DSG ([JPAC 25-43](#))

While ongoing work on donor consent will require a subsequent update to Chapter 3 of the Red Book, it was agreed that publication of CN 14-2025 should proceed as planned (18 July 2025) given the need to clarify guidance on the use of third-party interpreters in response to user feedback.

9.2. EDQM training course on Quality Management of SoHO

A free annual training course is now [open for registration](#) with an application deadline of 30 June 2025.

The course will be held online from 27 August to 13 October 2025.

10. Dates of future meetings

EWG	Wednesday 23 July 2025		
EWG	Thursday 09 October 2025	JPAC Board	Thursday 13 November 2025
EWG	Thursday 29 January 2026		
EWG	Thursday 26 February 2026	JPAC Board	Thursday 26 March 2026
EWG	Thursday 23 April 2026		
EWG	Thursday 21 May 2026	JPAC Board	Thursday 18 June 2026
EWG	Thursday 23 July 2026		
EWG	Thursday 22 October 2026	JPAC Board	Thursday 19 November 2026